Khorana_Risk_Score_Venous_Thromboembolism_Cancer_Patients v.0
Khorana Risk Score for Venous Thromboembolism in Cancer Patients predicts risk of VTE for cancer patients depending on type of cancer and other factors.
To predict risk of VTE for cancer patients depending on type of cancer and other factors.
Khorana Risk Score is calculated based on 5 parameters: Cancer type, Pre-chemotherapy platelet count ≥350x10⁹/L, Hemoglobin level <10 g/dL or using RBC growth factors, Pre-chemotherapy leukocyte count >11x10⁹/L and BMI ≥35 kg/m². Use in general cancer patients (i.e., solid tumors and lymphomas). Score interpretation: Risk Group Score 2.5-month rate of VTE Low 0 0.3 - 0.8% Intermediate 1 - 2 1.8 - 2.0% High ≥3 6.7 - 7.1%
Do not use in patients with brain tumors or myelomas.
1. Khorana AA, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7.
OBSERVATION.lab_test-full_blood_count.v1, EVALUATION.khorana_risk_score_venous_thromboembolism_cancer_patients.v0, OBSERVATION.body_mass_index.v2
